HCC-话题@MedSci

#HCC#

114篇内容 | 4662人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259550, encodeId=6ade125955006, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, objectType=article, longId=219974, objectId=ad462199e46a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad462199e46a, replyNumber=0, likeNumber=56, createdTime=2021-11-10, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad462199e46a, moduleTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad462199e46a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259549, encodeId=c3cc125954919, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：Gd-EOB-DTPA增强MRI放射组学对HCC组织学及患者预后的预测, objectType=article, longId=219717, objectId=4c2b219e17ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c2b219e17ec, replyNumber=0, likeNumber=51, createdTime=2021-11-05, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c2b219e17ec, moduleTitle=European Radiology：Gd-EOB-DTPA增强MRI放射组学对HCC组织学及患者预后的预测, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c2b219e17ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259548, encodeId=bf58125954832, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, objectType=article, longId=219491, objectId=16ac219491e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ac219491e4, replyNumber=0, likeNumber=70, createdTime=2021-10-31, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ac219491e4, moduleTitle=Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16ac219491e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259547, encodeId=c38b125954ed2, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, objectType=article, longId=219192, objectId=ab6d21919256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab6d21919256, replyNumber=0, likeNumber=109, createdTime=2021-10-26, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab6d21919256, moduleTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab6d21919256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259546, encodeId=858112595467c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, objectType=article, longId=219191, objectId=02ce219191a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02ce219191a0, replyNumber=0, likeNumber=58, createdTime=2021-10-26, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02ce219191a0, moduleTitle=Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02ce219191a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259545, encodeId=965712595454d, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗, objectType=article, longId=219167, objectId=456221916eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456221916eb9, replyNumber=0, likeNumber=49, createdTime=2021-10-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456221916eb9, moduleTitle=更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=456221916eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259544, encodeId=40681259544de, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性, objectType=article, longId=218274, objectId=25462182e412, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25462182e412, replyNumber=0, likeNumber=67, createdTime=2021-10-10, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25462182e412, moduleTitle=Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25462182e412)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259543, encodeId=868b12595433e, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, objectType=article, longId=217963, objectId=568c21e96338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=568c21e96338, replyNumber=0, likeNumber=69, createdTime=2021-10-02, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=568c21e96338, moduleTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=568c21e96338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259542, encodeId=fb72125954230, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：血清高骨保护素(OPG)水平是肝细胞癌(HCC)患者不良预后因素, objectType=article, longId=217877, objectId=804521e8770c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=804521e8770c, replyNumber=0, likeNumber=89, createdTime=2021-09-30, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=804521e8770c, moduleTitle=Front Oncol：血清高骨保护素(OPG)水平是肝细胞癌(HCC)患者不良预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=804521e8770c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259541, encodeId=316c1259541a6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期, objectType=article, longId=217593, objectId=2b2621e5937a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b2621e5937a, replyNumber=0, likeNumber=69, createdTime=2021-09-26, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b2621e5937a, moduleTitle=Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b2621e5937a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259540, encodeId=952f12595401c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！, objectType=article, longId=216224, objectId=35e921622426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35e921622426, replyNumber=0, likeNumber=83, createdTime=2021-08-25, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35e921622426, moduleTitle=Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35e921622426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259539, encodeId=ced012595391b, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology:MRI，让增殖型HCC“一眼到底”！, objectType=article, longId=216117, objectId=2d0a21611e9b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d0a21611e9b, replyNumber=0, likeNumber=88, createdTime=2021-08-23, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d0a21611e9b, moduleTitle=Radiology:MRI，让增殖型HCC“一眼到底”！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d0a21611e9b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259538, encodeId=69fc1259538d7, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法, objectType=article, longId=214858, objectId=0b4121485899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b4121485899, replyNumber=0, likeNumber=77, createdTime=2021-07-28, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b4121485899, moduleTitle=Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b4121485899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259537, encodeId=2e37125953e9c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：在预测HCC微血管浸润方面，MR并非想象中的可靠！, objectType=article, longId=214714, objectId=ba2c214e1427, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba2c214e1427, replyNumber=0, likeNumber=81, createdTime=2021-07-25, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba2c214e1427, moduleTitle=Radiology：在预测HCC微血管浸润方面，MR并非想象中的可靠！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba2c214e1427)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259536, encodeId=81c51259536b3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果, objectType=article, longId=214189, objectId=ceaa214189f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ceaa214189f7, replyNumber=0, likeNumber=64, createdTime=2021-07-15, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ceaa214189f7, moduleTitle=Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ceaa214189f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259535, encodeId=d1fc125953528, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, objectType=article, longId=213622, objectId=76842136220f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76842136220f, replyNumber=0, likeNumber=43, createdTime=2021-07-03, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76842136220f, moduleTitle=Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76842136220f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259534, encodeId=22b61259534fc, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology:对于HCC的诊断，不要只看动脉期！, objectType=article, longId=212732, objectId=4162212e3259, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4162212e3259, replyNumber=0, likeNumber=77, createdTime=2021-06-16, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4162212e3259, moduleTitle=Radiology:对于HCC的诊断，不要只看动脉期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4162212e3259)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259533, encodeId=a2d4125953320, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology:WHO引入了HCC新分型？快来看看它长什么样！ , objectType=article, longId=212528, objectId=6bb22125289a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bb22125289a, replyNumber=0, likeNumber=70, createdTime=2021-06-11, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bb22125289a, moduleTitle=Radiology:WHO引入了HCC新分型？快来看看它长什么样！ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bb22125289a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259532, encodeId=e4651259532c5, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Radiology：在HCC消融出现这一征象，是否提供更多的信息？LI-RADS 2018版MRI治疗反应算法的应用, objectType=article, longId=212482, objectId=d29f212482ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d29f212482ea, replyNumber=0, likeNumber=81, createdTime=2021-06-10, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d29f212482ea, moduleTitle=Radiology：在HCC消融出现这一征象，是否提供更多的信息？LI-RADS 2018版MRI治疗反应算法的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d29f212482ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259531, encodeId=8db5125953150, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。, objectType=article, longId=212415, objectId=b72721241538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b72721241538, replyNumber=0, likeNumber=68, createdTime=2021-06-09, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b72721241538, moduleTitle=Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b72721241538)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效

2021-11-10

仁医06 (审核中...)

前往app查看评论内容

#HCC#

European Radiology：Gd-EOB-DTPA增强MRI放射组学对HCC组织学及患者预后的预测

2021-11-05

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：肝切除术(HR)对比TACE治疗中期肝细胞癌(IM-HCC)的疗效

2021-10-31

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效

2021-10-26

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：卡瑞利珠单抗联合索拉非尼vs 索拉非尼单药治疗晚期肝细胞癌（HCC）的有效性和安全性

2021-10-26

仁医06 (审核中...)

前往app查看评论内容

#HCC#

更新！看更新版《中国肝细胞癌经动脉化疗栓塞治疗临床实践指南》谈接受介入治疗的HCC患者抗HBV治疗

2021-10-25

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Br J Cancer：基于白蛋白胆红素（ALBI）分级评估卡博替尼（cabozantinib）治疗晚期肝细胞癌（HCC）的疗效和安全性

2021-10-10

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效

2021-10-02

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：血清高骨保护素(OPG)水平是肝细胞癌(HCC)患者不良预后因素

2021-09-30

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：索拉非尼辅助治疗可改善高复发风险的肝细胞癌（HCC）患者切除术后的总生存期

2021-09-26

仁医06 (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：阿特珠单抗+贝伐单抗可显著延长中国晚期HCC患者的生存期！

2021-08-25

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology:MRI，让增殖型HCC“一眼到底”！

2021-08-23

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Nature：临床数据表明，仑伐替尼联合吉非替尼是晚期HCC的潜在疗法

2021-07-28

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：在预测HCC微血管浸润方面，MR并非想象中的可靠！

2021-07-25

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：雷莫芦单抗（Ramucirumab）治疗甲胎蛋白升高的中期肝细胞癌（HCC）患者的疗效:来自两项3期研究(REACH和REACH-2)的汇总结果

2021-07-15

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：卡瑞利珠单抗（Camrelizumab）治疗既往治疗进展的晚期肝细胞癌（HCC）患者的疗效：2期临床研究长期随访结果更新

2021-07-03

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology:对于HCC的诊断，不要只看动脉期！

2021-06-16

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology:WHO引入了HCC新分型？快来看看它长什么样！

2021-06-11

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Radiology：在HCC消融出现这一征象，是否提供更多的信息？LI-RADS 2018版MRI治疗反应算法的应用

2021-06-10

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。

2021-06-09

科室
- - 订阅+
  - 更多科室
工具
服务